Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

School of Pharmacy : Tam Yossi

Researchers

 Last updated June 2021 - School of Pharmacy

List of Publications

(1) Myers MN, Zachut M, Tam J, Contreras GA. A proposed modulatory role of the endocannabinoid system on adipose tissue metabolism and appetite in periparturient dairy cows. J Animal Sci Biotechnol 2021;12(1).

(2) Baraghithy S, Soae Y, Assaf D, Hinden L, Udi S, Drori A, et al. Renal Proximal Tubule Cell Cannabinoid-1 Receptor Regulates Bone Remodeling and Mass via a Kidney-to-Bone Axis. Cells 2021;10(2).

(3) Hinden L, Kogot-Levin A, Tam J, Leibowitz G. Pathogenesis of diabesity-induced kidney disease: role of kidney nutrient sensing. FEBS J 2021.

(4) Eger M, Bader M, Bree D, Hadar R, Nemirovski A, Tam J, et al. Author Correction: Bone Anabolic Response in the Calvaria Following Mild Traumatic Brain Injury is Mediated by the Cannabinoid-1 Receptor (Scientific Reports, (2019), 9, 1, (16196), 10.1038/s41598-019-51720-w). Sci Rep 2020;10(1).

(5) Azar S, Udi S, Drori A, Hadar R, Nemirovski A, Vemuri KV, et al. Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent. Mol Metab 2020;42.

(6) Drori A, Gammal A, Azar S, Hinden L, Hadar R, Wesley D, et al. Cb1r regulates soluble leptin receptor levels via chop, contributing to hepatic leptin resistance. eLife 2020;9:1-26.

(7) El-Atawneh S, Hirsch S, Hadar R, Tam J, Goldblum A. Erratum: Prediction and experimental confirmation of novel peripheral cannabinoid-1 receptor antagonists (J. Chem. Inf. Model. (2019) 59:9 (3996-4006) DOI: 10.1021/acs.jcim.9b00577). J Chem Inf Model 2020;60(10):5282.

(8) Chai C, Cox B, Yaish D, Gross D, Rosenberg N, Amblard F, et al. Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122. Gastroenterology 2020;159(3):999-1014.e9.

(9) Kogot-Levin A, Hinden L, Riahi Y, Israeli T, Tirosh B, Cerasi E, et al. Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 Inhibitors. Cell Rep 2020;32(4).

(10) Permyakova A, Gammal A, Hinden L, Weitman M, Weinstock M, Tam J. A Novel Indoline Derivative Ameliorates Diabesity-Induced Chronic Kidney Disease by Reducing Metabolic Abnormalities. Front Endocrinol 2020;11.

(11) Udi S, Hinden L, Ahmad M, Drori A, Iyer MR, Cinar R, et al. Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease. Br J Pharmacol 2020;177(1):110-127.

(12) Eger M, Bader M, Bree D, Hadar R, Nemerovski A, Tam J, et al. Bone Anabolic Response in the Calvaria Following Mild Traumatic Brain Injury is Mediated by the Cannabinoid-1 Receptor. Sci Rep 2019;9(1).

(13) Braxton TM, Sarpong DEA, Dovey JL, Guillou A, Evans BAJ, Castellano JM, et al. Thermoneutrality improves skeletal impairment in adult Prader-Willi syndrome mice. J Endocrinol 2019;243(3):175-186.

(14) Baraghithy S, Smoum R, Attar-Namdar M, Mechoulam R, Bab I, Tam J. Hu-671, a novel oleoyl serine derivative, exhibits enhanced efficacy in reversing ovariectomy-induced osteoporosis and bone marrow adiposity. Molecules 2019;24(20).

(15) El-Atawneh S, Hirsch S, Hadar R, Tam J, Goldblum A. Prediction and Experimental Confirmation of Novel Peripheral Cannabinoid-1 Receptor Antagonists. J Chem Inf Model 2019;59(9):3996-4006.

(16) Hinden L, Tam J. Do endocannabinoids regulate glucose reabsorption in the kidney? Nephron 2019;143(1):24-27.

(17) Hirsch S, Tam J. Cannabis: From a plant that modulates feeding behaviors toward developing selective inhibitors of the peripheral endocannabinoid system for the treatment of obesity and metabolic syndrome. Toxins 2019;11(5).

(18) Abu-Remaileh M, Abu-Remaileh M, Akkawi R, Knani I, Udi S, Pacold ME, et al. WWOX somatic ablation in skeletal muscles alters glucose metabolism. Mol Metab 2019;22:132-140.

(19) Aran A, Eylon M, Harel M, Polianski L, Nemirovski A, Tepper S, et al. Lower circulating endocannabinoid levels in children with autism spectrum disorder. Mol Autism 2019;10(1).

(20) Azar S, Sherf-Dagan S, Nemirovski A, Webb M, Raziel A, Keidar A, et al. Circulating Endocannabinoids Are Reduced Following Bariatric Surgery and Associated with Improved Metabolic Homeostasis in Humans. Obes Surg 2019;29(1):268-276.

(21) Drori A, Permyakova A, Hadar R, Udi S, Nemirovski A, Tam J. Cannabinoid-1 receptor regulates mitochondrial dynamics and function in renal proximal tubular cells. Diabetes Obes Metab 2019;21(1):146-159.

(22) Baraghithy S, Smoum R, Drori A, Hadar R, Gammal A, Hirsch S, et al. Magel2 Modulates Bone Remodeling and Mass in Prader-Willi Syndrome by Affecting Oleoyl Serine Levels and Activity. J Bone Miner Res 2019;34(1):93-105.

(23) Ganot N, Briaitbard O, Gammal A, Tam J, Hochman J, Tshuva EY. In Vivo Anticancer Activity of a Nontoxic Inert Phenolato Titanium Complex: High Efficacy on Solid Tumors Alone and Combined with Platinum Drugs. ChemMedChem 2018;13(21):2290-2296.

(24) Zachut M, Kra G, Moallem U, Livshitz L, Levin Y, Udi S, et al. Characterization of the endocannabinoid system in subcutaneous adipose tissue in periparturient dairy cows and its association to metabolic profiles. PLoS ONE 2018;13(11).

(25) Hanin G, Yayon N, Tzur Y, Haviv R, Bennett ER, Udi S, et al. miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression. Gut 2018;67(6):1124-1134.

(26) Tam J, Hinden L, Drori A, Udi S, Azar S, Baraghithy S. The therapeutic potential of targeting the peripheral endocannabinoid/CB1 receptor system. Eur J Intern Med 2018;49:23-29.

(27) Deis S, Srivastava RK, de Azua IR, Bindila L, Baraghithy S, Lutz B, et al. Age-related regulation of bone formation by the sympathetic cannabinoid CB1 receptor. Bone 2018;108:34-42.

(28) Hinden L, Udi S, Drori A, Gammal A, Nemirovski A, Hadar R, et al. Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy. J Am Soc Nephrol 2018;29(2):434-448.

(29) Udi S, Hinden L, Earley B, Drori A, Reuveni N, Hadar R, et al. Proximal tubular cannabinoid-1 receptor regulates obesity-induced CKD. J Am Soc Nephrol 2017;28(12):3518-3532.

(30) Drori A, Rotnemer-Golinkin D, Avni S, Drori A, Danay O, Levanon D, et al. Attenuating the rate of total body fat accumulation and alleviating liver damage by oral administration of vitamin D-enriched edible mushrooms in a diet-induced obesity murine model is mediated by an anti-inflammatory paradigm shift. BMC Gastroenterol 2017;17(1).

(31) Chai C, Rivkin M, Berkovits L, Simerzin A, Zorde-Khvalevsky E, Rosenberg N, et al. Metabolic Circuit Involving Free Fatty Acids, microRNA 122, and Triglyceride Synthesis in Liver and Muscle Tissues. Gastroenterology 2017;153(5):1404-1415.

(32) Tam J, Szanda G, Drori A, Liu Z, Cinar R, Kashiwaya Y, et al. Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling. Mol Metab 2017;6(10):1113-1125.

(33) Seltzman HH, Maitra R, Bortoff K, Henson J, Reggio PH, Wesley D, et al. Metabolic Profiling of CB1 Neutral Antagonists. Methods Enzymol 2017;593:199-215.

(34) Zelber-Sagi S, Azar S, Nemirovski A, Webb M, Halpern Z, Shibolet O, et al. Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease. Obesity 2017;25(1):94-101.

(35) Knani I, Earley BJ, Udi S, Nemirovski A, Hadar R, Gammal A, et al. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader–Willi syndrome. Mol Metab 2016;5(12):1187-1199.

(36) Tam J. The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases. J Basic Clin Physiol Pharmacol 2016;27(3):267-276.

(37) Godlewski G, Jourdan T, Szanda G, Tam J, Cinar R, Harvey-White J, et al. Mice lacking GPR3 receptors display late-onset obese phenotype due to impaired thermogenic function in brown adipose tissue. Sci Rep 2015;5.

(38) Park O, Ki SH, Xu M, Wang H, Feng D, Tam J, et al. Biologically active, high levels of interleukin-22 inhibit hepatic gluconeogenesis but do not affect obesity and its metabolic consequences. Cell Biosci 2015;5(1).

(39) Tam J. Role of the endocannabinoid system in hepatic lipogenesis. Hepatic De Novo Lipogenesis and Regulation of Metabolism; 2015. p. 131-142.

(40) Wasserman E, Tam J, Mechoulam R, Zimmer A, Maor G, Bab I. CB1 cannabinoid receptors mediate endochondral skeletal growth attenuation by Δ9-tetrahydrocannabinol. Ann New York Acad Sci 2015;1335(1):110-119.

(41) Jourdan T, Szandaa G, Rosenberg AZ, Tam J, Earley BJ, Godlewski G, et al. Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy. Proc Natl Acad Sci U S A 2014;111(50):E5420-E5428.

(42) Tam J, Godlewski G, Earley BJ, Zhou L, Jourdan T, Szanda G, et al. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity. Am J Physiol Endocrinol Metab 2014;306(4):E457-E468.

(43) Cinar R, Godlewski G, Liu J, Tam J, Jourdan T, Mukhopadhyay B, et al. Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides. Hepatology 2014;59(1):143-153.

(44) Silverman MN, Mukhopadhyay P, Belyavskaya E, Tonelli LH, Revenis BD, Doran JH, et al. Glucocorticoid receptor dimerization is required for proper recovery of LPS-induced inflammation, sickness behavior and metabolism in mice. Mol Psychiatry 2013;18(9):1006-1017.

(45) Jourdan T, Godlewski G, Cinar R, Bertola A, Szanda G, Liu J, et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med 2013;19(9):1132-1140.

(46) Tam J, Cinar R, Liu J, Godlewski G, Wesley D, Jourdan T, et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab 2012;16(2):167-179.

(47) Srivastava S, Kashiwaya Y, King MT, Baxa U, Tam J, Niu G, et al. Mitochondrial biogenesis and increased uncoupling protein 1 in brown adipose tissue of mice fed a ketone ester diet. FASEB J 2012;26(6):2351-2362.

(48) Liu J, Zhou L, Xiong K, Godlewski G, Mukhopadhyay B, Tam J, et al. Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology 2012;142(5):1218-1228.e1.

(49) Kunos G, Tam J. The case for peripheral CB 1 receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol 2011;163(7):1423-1431.

(50) Kunos G, Tam J. The case for peripheral CB 1 receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol 2011;163(7):1423-1431.

(51) Mukhopadhyay B, Cinar R, Yin S, Liu J, Tam J, Godlewski G, et al. Hyperactivation of anandamide synthesis and regulation of cell-Cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver. Proc Natl Acad Sci U S A 2011;108(15):6323-6328.

(52) Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G. Endocannabinoids in liver disease. Hepatology 2011;53(1):346-355.

(53) Godlewski G, Alapafuja SO, Bátkai S, Nikas SP, Cinar R, Offertáler L, et al. Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. Chem Biol 2010;17(11):1256-1266.

(54) Smoum R, Bar A, Tan B, Milman G, Attar-Namdar M, Ofek O, et al. Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci U S A 2010;107(41):17710-17715.

(55) Tam J, Vemuri VK, Liu J, Bátkai S, Mukhopadhyay B, Godlewski G, et al. Erratum: Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity (Journal of Clinical Investigation (2010) 120, 8, (2953-2966) DOI: 10.1172/JCI42551). J Clin Invest 2010;120(10):3735.

(56) Tam J, Vemuri VK, Liu J, Bátkai S, Mukhopadhyay B, Godlewski G, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010;120(8):2953-2966.

(57) Noh T, Gabet Y, Cogan J, Shi Y, Tank A, Sasaki T, et al. Lef1 haploinsufficient mice display a low turnover an low bone mass phenotype in a gender- and age- specific manner. PLoS ONE 2009;4(5).

(58) Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A. Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol 2008;20(SUPPL. 1):69-74.

(59) Tam J, Trembovler V, Di Marzo V, Petrosino S, Leo G, Alexandrovich A, et al. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J 2008;22(1):285-294.

(60) Yirmiya R, Goshen I, Bajayo A, Kreisel T, Feldman S, Tam J, et al. Depression induces bone loss through stimulation of the sympathetic nervous system. Proc Natl Acad Sci U S A 2006;103(45):16876-16881.

(61) Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A 2006;103(3):696-701.

(62) Tam J, Ofek O, Fride E, Ledent C, Gabet Y, M̈uller R, et al. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 2006;70(3):786-792.